Loading…
Beta cell function and response to treatment in Nigerians with Type 2 diabetes mellitus
There are scant data from African populations on the association between β-cell function and response to treatment with oral hypoglycaemic agents in Type 2 diabetes mellitus (T2DM). Fasting plasma C-peptide (FCP) and glucagon-stimulated C-peptide (GSCP) levels were measured in 116 Nigerians with T2D...
Saved in:
| Published in: | Diabetes research and clinical practice 2005-08, Vol.69 (2), p.196-204 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c363t-c985f4d6ab545df06095f7784f5d54563acf83ef4b1c9466b80e8c31e3d4f5773 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c363t-c985f4d6ab545df06095f7784f5d54563acf83ef4b1c9466b80e8c31e3d4f5773 |
| container_end_page | 204 |
| container_issue | 2 |
| container_start_page | 196 |
| container_title | Diabetes research and clinical practice |
| container_volume | 69 |
| creator | Oli, J.M. Adeyemo, A.A. Okafor, G.O. Ofoegbu, E.N. Onyenekwe, B. Chukwuka, C.J. Chen, G. Chen, Y. Doumatey, A.P. Aje, T.O. Rotimi, C.N. |
| description | There are scant data from African populations on the association between β-cell function and response to treatment with oral hypoglycaemic agents in Type 2 diabetes mellitus (T2DM). Fasting plasma C-peptide (FCP) and glucagon-stimulated C-peptide (GSCP) levels were measured in 116 Nigerians with T2DM at a university teaching hospital. After 9 months of follow-up and treatment, they were categorized into three groups based on response to treatment: (A) good control but not on maximum sulphonylurea (SU) therapy, (B) inadequate control but not on maximum SU therapy and (C) on maximum SU therapy
±
insulin or biguanide. Logistic regression models were used to investigate how well C-peptide levels predicted the subjects belonging to Group C who are likely to require insulin. The mean FCP and mean GSCP levels of Group C were significantly lower than in the other groups (
p
=
0.024;
p
= |
| doi_str_mv | 10.1016/j.diabres.2004.12.006 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68020494</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168822705000033</els_id><sourcerecordid>68020494</sourcerecordid><originalsourceid>FETCH-LOGICAL-c363t-c985f4d6ab545df06095f7784f5d54563acf83ef4b1c9466b80e8c31e3d4f5773</originalsourceid><addsrcrecordid>eNqFkMFuGyEQhlGVqnbcPkIiTrl5CwvL4lOUWG1TyWovrnpELAwJlpd1gE3kty9bW8oxJ0bom39mPoSuKKkooeLrrrJedxFSVRPCK1pXhIgPaE5lWy9lXbcXaF44-b-eocuUdqQQjDef0IwKQhrWkjn6ew9ZYwP7PXZjMNkPAetgcQk-DCEBzgPOEXTuIWTsA_7lHyF6HRJ-9fkJb48HwDWedoEMCfclyecxfUYfnd4n-HJ-F-jP92_b9cNy8_vHz_XdZmmYYHlpVrJx3ArdNbyxjgiyalzbSu4aW34E08ZJBo531Ky4EJ0kIA2jwGxB2pYt0M0p9xCH5xFSVr1P0zk6wDAmJSSpCV_xAjYn0MQhpQhOHaLvdTwqStRkVO3U2aiajCpaq8nXAl2fB4xdD_at66ywALcnAMqZLx6iSsZDMGB9BJOVHfw7I_4Bw-6J8w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68020494</pqid></control><display><type>article</type><title>Beta cell function and response to treatment in Nigerians with Type 2 diabetes mellitus</title><source>ScienceDirect Journals</source><creator>Oli, J.M. ; Adeyemo, A.A. ; Okafor, G.O. ; Ofoegbu, E.N. ; Onyenekwe, B. ; Chukwuka, C.J. ; Chen, G. ; Chen, Y. ; Doumatey, A.P. ; Aje, T.O. ; Rotimi, C.N.</creator><creatorcontrib>Oli, J.M. ; Adeyemo, A.A. ; Okafor, G.O. ; Ofoegbu, E.N. ; Onyenekwe, B. ; Chukwuka, C.J. ; Chen, G. ; Chen, Y. ; Doumatey, A.P. ; Aje, T.O. ; Rotimi, C.N.</creatorcontrib><description>There are scant data from African populations on the association between β-cell function and response to treatment with oral hypoglycaemic agents in Type 2 diabetes mellitus (T2DM). Fasting plasma C-peptide (FCP) and glucagon-stimulated C-peptide (GSCP) levels were measured in 116 Nigerians with T2DM at a university teaching hospital. After 9 months of follow-up and treatment, they were categorized into three groups based on response to treatment: (A) good control but not on maximum sulphonylurea (SU) therapy, (B) inadequate control but not on maximum SU therapy and (C) on maximum SU therapy
±
insulin or biguanide. Logistic regression models were used to investigate how well C-peptide levels predicted the subjects belonging to Group C who are likely to require insulin. The mean FCP and mean GSCP levels of Group C were significantly lower than in the other groups (
p
=
0.024;
p
=
<0.001 respectively). A GSCP cut-off value of ≤1.3
ng/mL predicted membership of Group C with 85% sensitivity and 89% specificity while a cut-off of ≤1.8
ng/mL was associated with 91% sensitivity and 66% specificity. In resource-poor settings where inadequate treatment are common, estimation of GSCP may be useful in predicting treatment response and should be weighed against the cost of inadequate therapy with higher morbidity and mortality.</description><identifier>ISSN: 0168-8227</identifier><identifier>EISSN: 1872-8227</identifier><identifier>DOI: 10.1016/j.diabres.2004.12.006</identifier><identifier>PMID: 16005370</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Beta-cell function ; Blood Glucose - metabolism ; Body Mass Index ; Body Size ; C-peptide ; C-Peptide - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - physiopathology ; Fasting ; Female ; Humans ; Islets of Langerhans - secretion ; Male ; Middle Aged ; Nigeria ; Nigerians ; Type 2 Diabetes mellitus</subject><ispartof>Diabetes research and clinical practice, 2005-08, Vol.69 (2), p.196-204</ispartof><rights>2005 Elsevier Ireland Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c363t-c985f4d6ab545df06095f7784f5d54563acf83ef4b1c9466b80e8c31e3d4f5773</citedby><cites>FETCH-LOGICAL-c363t-c985f4d6ab545df06095f7784f5d54563acf83ef4b1c9466b80e8c31e3d4f5773</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16005370$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oli, J.M.</creatorcontrib><creatorcontrib>Adeyemo, A.A.</creatorcontrib><creatorcontrib>Okafor, G.O.</creatorcontrib><creatorcontrib>Ofoegbu, E.N.</creatorcontrib><creatorcontrib>Onyenekwe, B.</creatorcontrib><creatorcontrib>Chukwuka, C.J.</creatorcontrib><creatorcontrib>Chen, G.</creatorcontrib><creatorcontrib>Chen, Y.</creatorcontrib><creatorcontrib>Doumatey, A.P.</creatorcontrib><creatorcontrib>Aje, T.O.</creatorcontrib><creatorcontrib>Rotimi, C.N.</creatorcontrib><title>Beta cell function and response to treatment in Nigerians with Type 2 diabetes mellitus</title><title>Diabetes research and clinical practice</title><addtitle>Diabetes Res Clin Pract</addtitle><description>There are scant data from African populations on the association between β-cell function and response to treatment with oral hypoglycaemic agents in Type 2 diabetes mellitus (T2DM). Fasting plasma C-peptide (FCP) and glucagon-stimulated C-peptide (GSCP) levels were measured in 116 Nigerians with T2DM at a university teaching hospital. After 9 months of follow-up and treatment, they were categorized into three groups based on response to treatment: (A) good control but not on maximum sulphonylurea (SU) therapy, (B) inadequate control but not on maximum SU therapy and (C) on maximum SU therapy
±
insulin or biguanide. Logistic regression models were used to investigate how well C-peptide levels predicted the subjects belonging to Group C who are likely to require insulin. The mean FCP and mean GSCP levels of Group C were significantly lower than in the other groups (
p
=
0.024;
p
=
<0.001 respectively). A GSCP cut-off value of ≤1.3
ng/mL predicted membership of Group C with 85% sensitivity and 89% specificity while a cut-off of ≤1.8
ng/mL was associated with 91% sensitivity and 66% specificity. In resource-poor settings where inadequate treatment are common, estimation of GSCP may be useful in predicting treatment response and should be weighed against the cost of inadequate therapy with higher morbidity and mortality.</description><subject>Beta-cell function</subject><subject>Blood Glucose - metabolism</subject><subject>Body Mass Index</subject><subject>Body Size</subject><subject>C-peptide</subject><subject>C-Peptide - blood</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - physiopathology</subject><subject>Fasting</subject><subject>Female</subject><subject>Humans</subject><subject>Islets of Langerhans - secretion</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nigeria</subject><subject>Nigerians</subject><subject>Type 2 Diabetes mellitus</subject><issn>0168-8227</issn><issn>1872-8227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNqFkMFuGyEQhlGVqnbcPkIiTrl5CwvL4lOUWG1TyWovrnpELAwJlpd1gE3kty9bW8oxJ0bom39mPoSuKKkooeLrrrJedxFSVRPCK1pXhIgPaE5lWy9lXbcXaF44-b-eocuUdqQQjDef0IwKQhrWkjn6ew9ZYwP7PXZjMNkPAetgcQk-DCEBzgPOEXTuIWTsA_7lHyF6HRJ-9fkJb48HwDWedoEMCfclyecxfUYfnd4n-HJ-F-jP92_b9cNy8_vHz_XdZmmYYHlpVrJx3ArdNbyxjgiyalzbSu4aW34E08ZJBo531Ky4EJ0kIA2jwGxB2pYt0M0p9xCH5xFSVr1P0zk6wDAmJSSpCV_xAjYn0MQhpQhOHaLvdTwqStRkVO3U2aiajCpaq8nXAl2fB4xdD_at66ywALcnAMqZLx6iSsZDMGB9BJOVHfw7I_4Bw-6J8w</recordid><startdate>20050801</startdate><enddate>20050801</enddate><creator>Oli, J.M.</creator><creator>Adeyemo, A.A.</creator><creator>Okafor, G.O.</creator><creator>Ofoegbu, E.N.</creator><creator>Onyenekwe, B.</creator><creator>Chukwuka, C.J.</creator><creator>Chen, G.</creator><creator>Chen, Y.</creator><creator>Doumatey, A.P.</creator><creator>Aje, T.O.</creator><creator>Rotimi, C.N.</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20050801</creationdate><title>Beta cell function and response to treatment in Nigerians with Type 2 diabetes mellitus</title><author>Oli, J.M. ; Adeyemo, A.A. ; Okafor, G.O. ; Ofoegbu, E.N. ; Onyenekwe, B. ; Chukwuka, C.J. ; Chen, G. ; Chen, Y. ; Doumatey, A.P. ; Aje, T.O. ; Rotimi, C.N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c363t-c985f4d6ab545df06095f7784f5d54563acf83ef4b1c9466b80e8c31e3d4f5773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Beta-cell function</topic><topic>Blood Glucose - metabolism</topic><topic>Body Mass Index</topic><topic>Body Size</topic><topic>C-peptide</topic><topic>C-Peptide - blood</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - physiopathology</topic><topic>Fasting</topic><topic>Female</topic><topic>Humans</topic><topic>Islets of Langerhans - secretion</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nigeria</topic><topic>Nigerians</topic><topic>Type 2 Diabetes mellitus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oli, J.M.</creatorcontrib><creatorcontrib>Adeyemo, A.A.</creatorcontrib><creatorcontrib>Okafor, G.O.</creatorcontrib><creatorcontrib>Ofoegbu, E.N.</creatorcontrib><creatorcontrib>Onyenekwe, B.</creatorcontrib><creatorcontrib>Chukwuka, C.J.</creatorcontrib><creatorcontrib>Chen, G.</creatorcontrib><creatorcontrib>Chen, Y.</creatorcontrib><creatorcontrib>Doumatey, A.P.</creatorcontrib><creatorcontrib>Aje, T.O.</creatorcontrib><creatorcontrib>Rotimi, C.N.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes research and clinical practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oli, J.M.</au><au>Adeyemo, A.A.</au><au>Okafor, G.O.</au><au>Ofoegbu, E.N.</au><au>Onyenekwe, B.</au><au>Chukwuka, C.J.</au><au>Chen, G.</au><au>Chen, Y.</au><au>Doumatey, A.P.</au><au>Aje, T.O.</au><au>Rotimi, C.N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Beta cell function and response to treatment in Nigerians with Type 2 diabetes mellitus</atitle><jtitle>Diabetes research and clinical practice</jtitle><addtitle>Diabetes Res Clin Pract</addtitle><date>2005-08-01</date><risdate>2005</risdate><volume>69</volume><issue>2</issue><spage>196</spage><epage>204</epage><pages>196-204</pages><issn>0168-8227</issn><eissn>1872-8227</eissn><abstract>There are scant data from African populations on the association between β-cell function and response to treatment with oral hypoglycaemic agents in Type 2 diabetes mellitus (T2DM). Fasting plasma C-peptide (FCP) and glucagon-stimulated C-peptide (GSCP) levels were measured in 116 Nigerians with T2DM at a university teaching hospital. After 9 months of follow-up and treatment, they were categorized into three groups based on response to treatment: (A) good control but not on maximum sulphonylurea (SU) therapy, (B) inadequate control but not on maximum SU therapy and (C) on maximum SU therapy
±
insulin or biguanide. Logistic regression models were used to investigate how well C-peptide levels predicted the subjects belonging to Group C who are likely to require insulin. The mean FCP and mean GSCP levels of Group C were significantly lower than in the other groups (
p
=
0.024;
p
=
<0.001 respectively). A GSCP cut-off value of ≤1.3
ng/mL predicted membership of Group C with 85% sensitivity and 89% specificity while a cut-off of ≤1.8
ng/mL was associated with 91% sensitivity and 66% specificity. In resource-poor settings where inadequate treatment are common, estimation of GSCP may be useful in predicting treatment response and should be weighed against the cost of inadequate therapy with higher morbidity and mortality.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>16005370</pmid><doi>10.1016/j.diabres.2004.12.006</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-8227 |
| ispartof | Diabetes research and clinical practice, 2005-08, Vol.69 (2), p.196-204 |
| issn | 0168-8227 1872-8227 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68020494 |
| source | ScienceDirect Journals |
| subjects | Beta-cell function Blood Glucose - metabolism Body Mass Index Body Size C-peptide C-Peptide - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - physiopathology Fasting Female Humans Islets of Langerhans - secretion Male Middle Aged Nigeria Nigerians Type 2 Diabetes mellitus |
| title | Beta cell function and response to treatment in Nigerians with Type 2 diabetes mellitus |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T19%3A21%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Beta%20cell%20function%20and%20response%20to%20treatment%20in%20Nigerians%20with%20Type%202%20diabetes%20mellitus&rft.jtitle=Diabetes%20research%20and%20clinical%20practice&rft.au=Oli,%20J.M.&rft.date=2005-08-01&rft.volume=69&rft.issue=2&rft.spage=196&rft.epage=204&rft.pages=196-204&rft.issn=0168-8227&rft.eissn=1872-8227&rft_id=info:doi/10.1016/j.diabres.2004.12.006&rft_dat=%3Cproquest_cross%3E68020494%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c363t-c985f4d6ab545df06095f7784f5d54563acf83ef4b1c9466b80e8c31e3d4f5773%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=68020494&rft_id=info:pmid/16005370&rfr_iscdi=true |